161 related articles for article (PubMed ID: 32584674)
1. Indications for Rituximab Use in an Integrated Health Care Delivery System.
Delate T; Hansen ML; Gutierrez AC; Le KN
J Manag Care Spec Pharm; 2020 Jul; 26(7):832-838. PubMed ID: 32584674
[TBL] [Abstract][Full Text] [Related]
2. The Profile of Use of Rituximab in Tertiary Care Hospitals of Central India.
Singh A; Sahoo AK; Biswal D; Sheth PG; Dhaneria S; Gupta D
J Pharm Bioallied Sci; 2022; 14(4):191-195. PubMed ID: 37051423
[TBL] [Abstract][Full Text] [Related]
3. Rituximab utilization for approved and off-label nononcology indications and patients' experiences with the Patient Alert Card.
Sarsour K; Beckley-Kartey S; Melega S; Odueyungbo A; Kirchner P; Khalife N; Bangs J
Pharmacol Res Perspect; 2020 Feb; 8(1):e00555. PubMed ID: 31911839
[TBL] [Abstract][Full Text] [Related]
4. Experience with low-dose rituximab in off-label indications at two tertiary hospitals.
Chay J; Donovan P; Cummins L; Kubler P; Pillans P
Intern Med J; 2013 Aug; 43(8):871-82. PubMed ID: 23919335
[TBL] [Abstract][Full Text] [Related]
5. Off-label use of rituximab in autoimmune disease in the Top End of the Northern Territory, 2008-2016.
Wongseelashote S; Tayal V; Bourke PF
Intern Med J; 2018 Feb; 48(2):165-172. PubMed ID: 28742259
[TBL] [Abstract][Full Text] [Related]
6. Prospective data collection of off-label use of rituximab in Australian public hospitals.
O'Connor K; Liddle C
Intern Med J; 2013 Aug; 43(8):863-70. PubMed ID: 23735074
[TBL] [Abstract][Full Text] [Related]
7. Adverse drug reactions after intravenous rituximab infusion are more common in hematologic malignancies than in autoimmune disorders and can be predicted by the combination of few clinical and laboratory parameters: results from a retrospective, multicenter study of 374 patients.
D'Arena G; Simeon V; Laurenti L; Cimminiello M; Innocenti I; Gilio M; Padula A; Vigliotti ML; De Lorenzo S; Loseto G; Passarelli A; Di Minno MND; Tucci M; De Feo V; D'Auria F; Silvestris F; Di Minno G; Musto P
Leuk Lymphoma; 2017 Nov; 58(11):2633-2641. PubMed ID: 28367662
[TBL] [Abstract][Full Text] [Related]
8. Application of the FDA Biosimilar Extrapolation Framework to Make Off-Label Determinations.
Li E; Lobaina E
J Manag Care Spec Pharm; 2017 Dec; 23(12):1227-1232. PubMed ID: 29172978
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of obinutuzumab versus rituximab biosimilars for previously untreated follicular lymphoma.
Spencer SJ; Guzauskas GF; FeLizzi F; Launonen A; Dawson K; Veenstra DL; Masaquel A
J Manag Care Spec Pharm; 2021 May; 27(5):615-624. PubMed ID: 33586513
[No Abstract] [Full Text] [Related]
10. Repurposing of rituximab biosimilars to treat B cell mediated autoimmune diseases.
Mostkowska A; Rousseau G; Raynal NJ
FASEB J; 2024 Mar; 38(5):e23536. PubMed ID: 38470360
[TBL] [Abstract][Full Text] [Related]
11. A Randomized, Double-Blind Study Comparing Pharmacokinetics and Pharmacodynamics of Proposed Biosimilar ABP 798 With Rituximab Reference Product in Subjects With Moderate to Severe Rheumatoid Arthritis.
Burmester G; Chien D; Chow V; Gessner M; Pan J; Cohen S
Clin Pharmacol Drug Dev; 2020 Nov; 9(8):1003-1014. PubMed ID: 32627420
[TBL] [Abstract][Full Text] [Related]
12. Drug, patient, and physician characteristics associated with off-label prescribing in primary care.
Eguale T; Buckeridge DL; Winslade NE; Benedetti A; Hanley JA; Tamblyn R
Arch Intern Med; 2012 May; 172(10):781-8. PubMed ID: 22507695
[TBL] [Abstract][Full Text] [Related]
13. Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study.
Bromberg JEC; Issa S; Bakunina K; Minnema MC; Seute T; Durian M; Cull G; Schouten HC; Stevens WBC; Zijlstra JM; Baars JW; Nijland M; Mason KD; Beeker A; van den Bent MJ; Beijert M; Gonzales M; de Jong D; Doorduijn JK
Lancet Oncol; 2019 Feb; 20(2):216-228. PubMed ID: 30630772
[TBL] [Abstract][Full Text] [Related]
14. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
15. GP2013: A Rituximab Biosimilar.
Blair HA
BioDrugs; 2017 Oct; 31(5):465-468. PubMed ID: 28921160
[TBL] [Abstract][Full Text] [Related]
16. Factors Associated With Complete Remission After Rituximab Therapy for Pemphigus.
Kushner CJ; Wang S; Tovanabutra N; Tsai DE; Werth VP; Payne AS
JAMA Dermatol; 2019 Dec; 155(12):1404-1409. PubMed ID: 31642878
[TBL] [Abstract][Full Text] [Related]
17. Initial and supplementary indication approval of new targeted cancer drugs by the FDA, EMA, Health Canada, and TGA.
Michaeli DT; Mills M; Michaeli T; Miracolo A; Kanavos P
Invest New Drugs; 2022 Aug; 40(4):798-809. PubMed ID: 35389145
[TBL] [Abstract][Full Text] [Related]
18. Off-label use of second-generation antipsychotic agents among elderly nursing home residents.
Kamble P; Sherer J; Chen H; Aparasu R
Psychiatr Serv; 2010 Feb; 61(2):130-6. PubMed ID: 20123817
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of a Clinical Pharmacist Medication Therapy Management Program in Discontinuation of Drugs to Avoid in the Elderly.
Caffiero N; Delate T; Ehizuelen MD; Vogel K
J Manag Care Spec Pharm; 2017 May; 23(5):525-531. PubMed ID: 28448783
[TBL] [Abstract][Full Text] [Related]
20. Patterns of Care for Biologic-Dosing Outliers and Nonoutliers in Biologic-Naive Patients with Rheumatoid Arthritis.
Delate T; Meyer R; Jenkins D
J Manag Care Spec Pharm; 2017 Aug; 23(8):798-808. PubMed ID: 28737988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
